These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 12782574

  • 1. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
    Nanni P, Nicoletti G, De Giovanni C, Croci S, Astolfi A, Landuzzi L, Di Carlo E, Iezzi M, Musiani P, Lollini PL.
    Cancer Res; 2003 Jun 01; 63(11):2728-32. PubMed ID: 12782574
    [Abstract] [Full Text] [Related]

  • 2. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
    Ianzano ML, Croci S, Nicoletti G, Palladini A, Landuzzi L, Grosso V, Ranieri D, Dall'Ora M, Santeramo I, Urbini M, De Giovanni C, Lollini PL, Nanni P.
    Oncotarget; 2014 Jan 15; 5(1):108-19. PubMed ID: 24334679
    [Abstract] [Full Text] [Related]

  • 3. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
    Brodie SG, Xu X, Li C, Kuo A, Leder P, Deng CX.
    Oncogene; 2001 Mar 22; 20(12):1445-54. PubMed ID: 11313888
    [Abstract] [Full Text] [Related]

  • 4. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M, Papalini F, Orlando F, Pierpaoli S, Donnini A, Morazzoni P, Riva A, Smorlesi A.
    Cancer Res; 2007 Mar 01; 67(5):2022-9. PubMed ID: 17332330
    [Abstract] [Full Text] [Related]

  • 5. Immunological prevention of a multigene cancer syndrome.
    Croci S, Nicoletti G, Landuzzi L, De Giovanni C, Astolfi A, Marini C, Di Carlo E, Musiani P, Forni G, Nanni P, Lollini PL.
    Cancer Res; 2004 Nov 15; 64(22):8428-34. PubMed ID: 15548714
    [Abstract] [Full Text] [Related]

  • 6. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A.
    Nature; 1992 Mar 19; 356(6366):215-21. PubMed ID: 1552940
    [Abstract] [Full Text] [Related]

  • 7. p53 and Her-2/neu in juvenile angiofibromas.
    Schick B, Veldung B, Wemmert S, Jung V, Montenarh M, Meese E, Urbschat S.
    Oncol Rep; 2005 Mar 19; 13(3):453-7. PubMed ID: 15706416
    [Abstract] [Full Text] [Related]

  • 8. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, Modesti M, Forni G, Kraus MH, Muraro R, Modesti A, Bei R.
    Int J Oncol; 2007 Feb 19; 30(2):381-92. PubMed ID: 17203220
    [Abstract] [Full Text] [Related]

  • 9. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
    Duan W, Ding H, Subler MA, Zhu WG, Zhang H, Stoner GD, Windle JJ, Otterson GA, Villalona-Calero MA.
    Oncogene; 2002 Nov 07; 21(51):7831-8. PubMed ID: 12420220
    [Abstract] [Full Text] [Related]

  • 10. Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.
    Izzotti A, Cartiglia C, Longobardi M, Bagnasco M, Merello A, You M, Lubet RA, De Flora S.
    Cancer Res; 2004 Dec 01; 64(23):8566-72. PubMed ID: 15574763
    [Abstract] [Full Text] [Related]

  • 11. [Rhabdomyosarcoma development in Trp53/fos mutant mice: tumor suppressor functions of the Fos protooncogene].
    Jochum W.
    Verh Dtsch Ges Pathol; 2004 Dec 01; 88():224-30. PubMed ID: 16892556
    [Abstract] [Full Text] [Related]

  • 12. Targeted inactivation of p53 in human cells does not result in aneuploidy.
    Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, Vogelstein B, Lengauer C.
    Cancer Res; 2002 Feb 15; 62(4):1129-33. PubMed ID: 11861393
    [Abstract] [Full Text] [Related]

  • 13. p53 family members in myogenic differentiation and rhabdomyosarcoma development.
    Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Hüttinger-Kirchhof N, Oswald C, Friedl P, Gattenlöhner S, Burek C, Rosenwald A, Stiewe T.
    Cancer Cell; 2006 Oct 15; 10(4):281-93. PubMed ID: 17045206
    [Abstract] [Full Text] [Related]

  • 14. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA.
    Anticancer Res; 2005 Oct 15; 25(1B):635-41. PubMed ID: 15816639
    [Abstract] [Full Text] [Related]

  • 15. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.
    Cancer Res; 2004 Nov 01; 64(21):8022-8. PubMed ID: 15520211
    [Abstract] [Full Text] [Related]

  • 16. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.
    Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K, Suzuki N.
    Oncogene; 2006 Dec 14; 25(59):7673-9. PubMed ID: 16785989
    [Abstract] [Full Text] [Related]

  • 17. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.
    Hayakawa Y, Rovero S, Forni G, Smyth MJ.
    Proc Natl Acad Sci U S A; 2003 Aug 05; 100(16):9464-9. PubMed ID: 12867593
    [Abstract] [Full Text] [Related]

  • 18. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
    Elgavish A, Wood PA, Pinkert CA, Eltoum IE, Cartee T, Wilbanks J, Mentor-Marcel R, Tian L, Scroggins SE.
    Prostate; 2004 Sep 15; 61(1):26-34. PubMed ID: 15287091
    [Abstract] [Full Text] [Related]

  • 19. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T, Nakazawa M, Yura Y, Hamaoka T, Fujiwara H.
    Cancer Res; 2004 Oct 15; 64(20):7588-95. PubMed ID: 15492286
    [Abstract] [Full Text] [Related]

  • 20. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
    Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EY.
    Cancer Res; 2004 May 15; 64(10):3525-32. PubMed ID: 15150107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.